Bo Jan Noordman

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Bo Jan Noordman, Manon C.W. Spaander, Roelf Valkema et al. · The Lancet Oncology · 2018 · 332 citations

Medicine, Oncology, Surgery +17

Effectiveness of First‐Line Treatment With Recombinant Interleukin‐1 Receptor Antagonist in Steroid‐Naive Patients With New‐Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

Sebastiaan J. Vastert, Wilco de Jager, Bo Jan Noordman et al. · Arthritis & Rheumatology · 2013 · 263 citations

Life Sciences, Immunology, Pharmacotherapy +14

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial

Bo Jan Noordman, Bas P. L. Wijnhoven, Sjoerd M. Lagarde et al. · BMC Cancer · 2018 · 245 citations · Full text

Medicine, Oncology, Surgery +17

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial

Bo Jan Noordman, Mathilde G. E. Verdam, Sjoerd M. Lagarde et al. · Journal of Clinical Oncology · 2017 · 129 citations · Full text

Medicine, Oncology, Surgery +17

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial

Berend J. van der Wilk, Ben M. Eyck, Bas P. L. Wijnhoven et al. · The Lancet Oncology · 2025 · 90 citations · Full text

Medicine, Oncology, Surgery +17